Occult Histological Fibrosis: An Underrecognized Risk Factor for Postoperative Respiratory Morbidity After Minimally Invasive Anatomical Lung Resection
This study reveals that occult histological fibrosis is a frequent, largely unrecognized finding in patients undergoing minimally invasive lung resection, with significant fibrosis independently predicting an increased risk of postoperative respiratory morbidity.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a surgeon removes a portion of a lung to treat cancer, the goal is to leave the patient with enough healthy tissue to breathe easily afterward. For decades, doctors have known that patients with a known history of scarring in their lungs face a much higher risk of serious breathing trouble after such an operation. To avoid this, surgeons rely on preoperative scans and breathing tests to spot these patients before they go under anesthesia. However, these standard tools are not perfect. They can miss very early or subtle signs of lung damage that have not yet caused symptoms or shown up clearly on an image. This leaves a gap in knowledge: how many patients are walking into the operating room with hidden lung scarring that the medical team never saw, and does this invisible damage actually change their recovery?
A team of researchers at hospitals in Spain and Italy set out to answer this question by looking back at the records of patients who had undergone minimally invasive lung surgery between 2023 and 2026. Minimally invasive surgery is a modern approach where surgeons use small incisions and specialized cameras rather than large open cuts, a technique that generally helps patients recover faster. The researchers focused on a specific group of 669 patients who had their lungs examined after the operation. While the surgeons had already removed the cancerous tissue, the pathologists who studied the removed tissue under a microscope also looked at the surrounding, healthy-looking lung tissue for any signs of fibrosis, which is the medical term for stiff, scarred lung tissue.
The study revealed a striking reality: nearly one in ten patients had evidence of lung scarring in their tissue samples, yet the vast majority of these cases were completely unknown to the doctors before the surgery began. Out of the 669 people, 77 had some form of fibrosis. Only nine of them had been diagnosed with a lung disease beforehand. The other 68 patients had what the researchers call "occult" fibrosis, meaning the scarring was hidden and undetected during the routine checks. In total, about 88 percent of the fibrotic abnormalities found in the study were missed by the standard preoperative evaluation. This suggests that a significant number of people undergoing lung surgery carry a biological burden of lung damage that current screening methods fail to catch.
The researchers then asked whether this hidden scarring actually mattered for the patients' recovery. They compared the postoperative outcomes of those with hidden fibrosis against those with no fibrosis at all. The data showed a clear trend: patients with hidden fibrosis experienced more breathing complications after surgery than those with healthy lungs. However, when the researchers adjusted for other factors like age and the size of the surgery, the link became slightly less certain, hovering just below the threshold of statistical proof. This hinted that while the hidden scarring was a risk, the picture was complicated by the wide variety of scarring patterns found.
To get a clearer picture, the team sorted the patients based on how severe the scarring was. They divided the findings into two groups: mild fibrosis, which consisted of small, isolated patches of scarring, and significant fibrosis, which involved more widespread or extensive damage. When they looked at the results through this lens, a distinct pattern emerged. Patients with mild, limited scarring did not have a higher risk of breathing problems compared to those with no scarring. But for the patients with significant, extensive fibrosis, the risk of postoperative respiratory complications was nearly three times higher than for those with healthy lungs. This distinction is crucial because it suggests that not all hidden lung damage is dangerous; rather, it is the extent of the scarring that determines the risk.
The study also noted that the small group of patients who did have a known history of lung disease before surgery did not show the same high rate of complications as one might expect. The authors suggest this is likely because these specific patients were already receiving specialized medication to treat their condition, which may have helped protect them during the operation. This highlights that while the hidden scarring in the other patients was a surprise, the medical community has effective ways to manage known disease when it is identified early.
Ultimately, these findings point to a limitation in how surgeons currently assess risk. The standard preoperative checks are good at finding obvious disease, but they often miss the early, subtle stages of lung scarring that can still cause trouble after an operation. The research indicates that the mere presence of a tiny scar is not necessarily a cause for alarm, but when the scarring is extensive, it acts as a strong warning sign. This suggests that in the future, finding better ways to detect these more severe forms of hidden fibrosis before surgery could help doctors identify high-risk patients. By recognizing who is truly at risk, medical teams could potentially offer closer monitoring or different care plans after the operation, ensuring that the benefits of modern, minimally invasive surgery are not undermined by unseen lung damage.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.